Image credits: APOTEX
/
News Article

Apotex: Patient-Centric Portfolio for Latin American Patients

By Miriam Bello | Mon, 10/25/2021 - 13:46

Apotex presence in Mexico goes back to 1996, when the pharmaceutical industry was not focused on generics because the country was a brand-focused market. To date, the company’s footprint in the country can be reflected in their pharmaceutical sales and manufacturing as Apotex has a finished product plant, R&D laboratories and pharmaceutical-chemical plants for APIs, making Apotex the only company with API production and complete product manufacturing in both Canada and Mexico.

Apotex allocates 12 percent of its sales in Mexico to R&D and technological innovation as part of its commitment in keeping up-to-date and being on par with the market. Their presence in this market places Apotex among the top 10 companies in units in Mexico’s generic market, allowing the company to have a double digit grown in the brand market.

This market success comes hand in hand with delivering quality, safety and effectiveness in their medicines, which today, responds to 36 therapeutical areas, among those stand out:

- Gastroenterology

- Cardiology

- Erectile dysfunction

-Nervous system

More specifically and mainly supporting the needs of the market and of patients, Apotex's Erectile Dysfunction portfolio has two options for the treatment of this disease: Sildenafil and Tadalafil.

Erectile Dysfunction

ED is a common global care problem that presents particularly in men over 40. In Mexico, this disease affects approximately 55 percent of men between the ages of 40 and 70, who suffer from diabetes mellitus.

It is not only a sexual health problem, it can also be caused by surgery, an injury to the penis, the spine, the prostate, the bladder or the pelvis.

There are several health factors that can led to ED, such as cardiovascular or metabolic disease, diabetes or chronic alcoholism. Likewise, ED can lead develop emotional disorders such as depression.

There is a 5 percent perveance of ED in men 40 years of age, increasing to 15 percent to 25 percent at age 65 years and older. As a result, these men tend to present unipolar depressive disorders, such as major depressive disorder (MDD) and milder depressive syndromes affect 10 percent to 20 percent of men. Among elderly men, milder depressive syndromes appear to be more common.

Although comorbidity between ED and depressive illness is apparently high, the causal relationship is unclear. ED and the psychosocial distress that often accompanies it may trigger the development of depressive illness in vulnerable individuals; depression may induce a third factor, such as substance abuse or medical illness, may cause both conditions; or these conditions may be etiologically unrelated and are comorbid simply because of their high prevalence, particularly in older men.

Studies by the College of Physicians and Surgeons of Columbia University have demonstrated a strong positive correlation between ED and reduced quality of life, impaired social and occupational functioning, and substance abuse.

Treatment of Erectile Dysfunction

In 1998, FDA approved the first “on-demand” oral medication for the treatment of ED, called sildenafil. Sildenafil is an oral therapy for erectile dysfunction of a broad range of causes. By selectively inhibiting phosphodiesterase type 5, it allows corpus cavernosum smooth muscle to relax, potentiating erections during sexual stimulation.

Sildenafil has demonstrated significant efficacy in ED associated with primarily psychogenic, primarily organic, and mixed etiologies in worldwide clinical trials. It is not effective in the absence of sexual stimulation.

Tadalafil, alongside sildenafil, are the two most common phosphodiesterase 5 inhibitors used to treat ED. A study by the Nanchang University, conducted an analysis to directly compare tadalafil with sildenafil for the treatment of ED.

A total of 16 trials that compared tadalafil with sildenafil for the treatment of ED found that tadalafil and sildenafil appeared to have similar efficacies and overall adverse event rates. However, compared with sildenafil, tadalafil significantly improved psychological outcomes. Further- more, the patients and their partners preferred tadalafil over sildenafil, and no significant difference was found in the adherence and persistence rates between tadalafil and sildenafil.

The results concluded that tadalafil shares a similar efficacy and safety with sildenafil and significantly improves patients’ sexual confidence. Furthermore, patients and their partners prefer tadalafil to sildenafil. Hence, tadalafil may be a better choice for ED treatment.

Apotex has consistently demonstrated quality, safety and effectiveness of its medicines, today it occupies the third place in values and is within the top 10 in units in the generic market and growing at double digits in the brand market, adapting to new forms of consumption that current circumstances have imposed on us. It is for this reason, that the company’s sildenafil and tadalafil offer the same excellence consistency.

The data used in this article was sourced from:  
Nanchang University, Columbia University, Revista Mexicana de Urología, International Journal of Impotence Research
Photo by:   APOTEX
Miriam Bello Miriam Bello Journalist and Industry Analyst